Back to Search Start Over

A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma

Authors :
Medicina
Medikuntza
Macias, Rocio I. R.
Muñoz Bellvís, Luis
Sánchez Martín, Anabel
Arretxe Oliden, Enara
Martínez Arranz, Ibon
Lapitz Damborenea, Ainhoa
Gutiérrez, M. Laura
La Casta, Adelaida
Alonso, Cristina
González, Luis M.
Avila, Matias A.
Martinez-Chantar, Maria L.
Castro, Rui E.
Bujanda Fernández de Pierola, Luis
Bañales Asurmendi, Jesús María
Marin, José J. G.
Medicina
Medikuntza
Macias, Rocio I. R.
Muñoz Bellvís, Luis
Sánchez Martín, Anabel
Arretxe Oliden, Enara
Martínez Arranz, Ibon
Lapitz Damborenea, Ainhoa
Gutiérrez, M. Laura
La Casta, Adelaida
Alonso, Cristina
González, Luis M.
Avila, Matias A.
Martinez-Chantar, Maria L.
Castro, Rui E.
Bujanda Fernández de Pierola, Luis
Bañales Asurmendi, Jesús María
Marin, José J. G.
Publication Year :
2020

Abstract

The diagnosis of adenocarcinomas located in the pancreas head, i.e., distal cholangiocarcinoma (dCCA) and pancreatic ductal adenocarcinoma (PDAC), constitutes a clinical challenge because they share many symptoms, are not easily distinguishable using imaging techniques and accurate biomarkers are not available. Searching for biomarkers with potential usefulness in the differential diagnosis of these tumors, we have determined serum metabolomic profiles in healthy controls and patients with dCCA, PDAC or benign pancreatic diseases (BPD). Ultra-high-performance liquid chromatography coupled to mass spectrometry (UHPLC-MS) analysis was performed in serum samples from dCCA (n = 34), PDAC (n = 38), BPD (n = 42) and control (n = 25) individuals, divided into discovery and validation cohorts. This approach permitted 484 metabolites to be determined, mainly lipids and amino acids. The analysis of the results led to the proposal of a logistic regression model able to discriminate patients with dCCA and PDAC (AUC value of 0.888) based on the combination of serum levels of nine metabolites (acylcarnitine AC(16:0), ceramide Cer(d18:1/24:0), phosphatidylcholines PC(20:0/0:0) and PC(O-16:0/20:3), lysophosphatidylcholines PC(20:0/0:0) and PC(0:0/20:0), lysophosphatidylethanolamine PE(P-18:2/0:0), and sphingomyelins SM(d18:2/22:0) and SM(d18:2/23:0)) and CA 19-9. In conclusion, we propose a novel specific panel of serum metabolites that can help in the differential diagnosis of dCCA and PDAC. Further validation of their clinical usefulness in prospective studies is required.

Details

Database :
OAIster
Notes :
This study was supported by the Centro Internacional sobre el Envejecimiento, Spain (OLD-HEPAMARKER, 0348_CIE_6_E) co-financed with European Union ERDF funds; Carlos III Institute of Health, Spain (PI16/00598, PI16/01126, PI18/01075, PI19/00819) and Miguel Servet Program (CON14/00129) co-financed by European Regional Development Fund; Asociación Española Contra el Cancer, Spain (AECC-Cánceres raros 2017/2020); H2020 ESCALON project: H2020-SC1-BHC-2018-2020; Fundacion La Caixa (Hepacare Project); MCIU/AEI/FEDER, EU (SAF2017-87301-R); Severo Ochoa Excellence Accreditation (SEV-2016-0644). A. Sanchez-Martin and A. Lapitz were supported by pre-doctoral scholarships funded by the Ministry of Science, Innovation and Universities (FPU17/04027) and the Basque Government (PRE_2017_1_0345), respectively, and M.L. Gutiérrez is supported by the "Stop fuga de Cerebros" grant from ROCHE FARMA SA. This work was carried out in the framework of Working Group 5 of the COST Action CA18122, European Cholangiocarcinoma Network, EURO-CHOLANGIO-NET., English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1202406570
Document Type :
Electronic Resource